Literature DB >> 22305342

Synthesis of chromeno[3,4-b]indoles as Lamellarin D analogues: a novel DYRK1A inhibitor class.

Cleopatra Neagoie1, Emeline Vedrenne, Frédéric Buron, Jean-Yves Mérour, Sorin Rosca, Stéphane Bourg, Olivier Lozach, Laurent Meijer, Brigitte Baldeyrou, Amelie Lansiaux, Sylvain Routier.   

Abstract

A library of substituted chromeno[3,4-b]indoles was developed as Lamellarin isosters. Synthesis was achieved from indoles after a four-step pathway sequence involving C-3 iodination, a Suzuki cross-coupling reaction, and a one pot deprotection/lactonisation step. Twenty final compounds were tested in order to determine their activity against topoisomerase I and kinases, the two major biological activities of Lamellarins. One newly synthesized derivative exhibited a strong topoisomerase activity comparable to reference compounds such as campthotecin and Lamellarin with only a weak kinase inhibition. Two other lead compounds were identified as new nanomolar DYRK1A inhibitors and several other drugs affected the kinases in the sub-micromolar range. These results will enable us to use the chromeno[3,4-b]indole as a pharmacophore to develop potent treatments for neurological or oncological disorders in which DYRK1A is fully involved. Copyright Â
© 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22305342     DOI: 10.1016/j.ejmech.2012.01.040

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  20 in total

1.  Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation.

Authors:  Kunal Kumar; Peng Wang; Roberto Sanchez; Ethan A Swartz; Andrew F Stewart; Robert J DeVita
Journal:  J Med Chem       Date:  2018-08-21       Impact factor: 7.446

2.  Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity.

Authors:  Kunal Kumar; Peter Man-Un Ung; Peng Wang; Hui Wang; Hailing Li; Mary K Andrews; Andrew F Stewart; Avner Schlessinger; Robert J DeVita
Journal:  Eur J Med Chem       Date:  2018-08-22       Impact factor: 6.514

3.  Novel and Potential Small Molecule Scaffolds as DYRK1A Inhibitors by Integrated Molecular Docking-Based Virtual Screening and Dynamics Simulation Study.

Authors:  Mir Mohammad Shahroz; Hemant Kumar Sharma; Abdulmalik S A Altamimi; Mubarak A Alamri; Abuzer Ali; Amena Ali; Safar Alqahtani; Ali Altharawi; Alhumaidi B Alabbas; Manal A Alossaimi; Yassine Riadi; Ahmad Firoz; Obaid Afzal
Journal:  Molecules       Date:  2022-02-09       Impact factor: 4.411

4.  Design and biological evaluation of substituted 5,7-dihydro-6H-indolo[2,3-c]quinolin-6-one as novel selective Haspin inhibitors.

Authors:  Sreenivas Avula; Xudan Peng; Xingfen Lang; Micky Tortorella; Béatrice Josselin; Stéphane Bach; Stephane Bourg; Pascal Bonnet; Frédéric Buron; Sandrine Ruchaud; Sylvain Routier; Cleopatra Neagoie
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

5.  Synthesis and HPLC-ECD Study of Cytostatic Condensed O,N-Heterocycles Obtained from 3-Aminoflavanones.

Authors:  Ádám Szappanos; Attila Mándi; Katalin Gulácsi; Erika Lisztes; Balázs István Tóth; Tamás Bíró; Anita Kónya-Ábrahám; Attila Kiss-Szikszai; Attila Bényei; Sándor Antus; Tibor Kurtán
Journal:  Biomolecules       Date:  2020-10-20

Review 6.  Current pharmacotherapy and putative disease-modifying therapy for Alzheimer's disease.

Authors:  Akanksha Kulshreshtha; Poonam Piplani
Journal:  Neurol Sci       Date:  2016-06-01       Impact factor: 3.307

Review 7.  Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?

Authors:  Breland Smith; Federico Medda; Vijay Gokhale; Travis Dunckley; Christopher Hulme
Journal:  ACS Chem Neurosci       Date:  2012-08-28       Impact factor: 4.418

Review 8.  Marine Pyrrole Alkaloids.

Authors:  Kevin Seipp; Leander Geske; Till Opatz
Journal:  Mar Drugs       Date:  2021-09-10       Impact factor: 5.118

Review 9.  Anticancer properties of lamellarins.

Authors:  Christian Bailly
Journal:  Mar Drugs       Date:  2015-02-19       Impact factor: 5.118

10.  Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor.

Authors:  Kunal Kumar; Peng Wang; Jessica Wilson; Viktor Zlatanic; Cecilia Berrouet; Susmita Khamrui; Cody Secor; Ethan A Swartz; Michael Lazarus; Roberto Sanchez; Andrew F Stewart; Adolfo Garcia-Ocana; Robert J DeVita
Journal:  J Med Chem       Date:  2020-02-19       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.